Completed Access to Information Requests

Follow:

  • RSS
  • Cite

    Cite

    APA

    Open Government - Government of Canada. (2017, December 10). Completed Access to Information Requests. Retrieved from http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&amp%3Bamp%3Bf%5B1%5D=ss_ati_organization_en%3ATransportation%20Safety%20Board%20of%20Canada&amp%3Bamp%3Bf%5B2%5D=ss_ati_organization_en%3APublic%20Health%20Agency%20of%20Canada&amp%3Bamp%3Bati%5B0%5D=ss_ati_organization_en%3ACanadian%20Transportation%20Agency&amp%3Bamp%3Bati%5B1%5D=ss_ati_organization_en%3AMilitary%20Grievances%20External%20Review%20Committee&amp%3Bati%5B0%5D=ss_ati_monthname_en%3ANovember&ati%5B0%5D=ati_month_en%3AJuly&ati%5B1%5D=ati_month_en%3AMarch&ati%5B2%5D=ati_organization_en%3APatented%20Medicine%20Prices%20Review%20Board%20Canada
    MLA

    “Completed Access to Information Requests.” Open Government - Government of Canada, 10 December 2017, http://open.canada.ca/en/search/ati?f%5B0%5D=ss_ati_organization_en%3AAtomic%20Energy%20of%20Canada%20Limited&amp%3Bamp%3Bf%5B1%5D=ss_ati_organization_en%3ATransportation%20Safety%20Board%20of%20Canada&amp%3Bamp%3Bf%5B2%5D=ss_ati_organization_en%3APublic%20Health%20Agency%20of%20Canada&amp%3Bamp%3Bati%5B0%5D=ss_ati_organization_en%3ACanadian%20Transportation%20Agency&amp%3Bamp%3Bati%5B1%5D=ss_ati_organization_en%3AMilitary%20Grievances%20External%20Review%20Committee&amp%3Bati%5B0%5D=ss_ati_monthname_en%3ANovember&ati%5B0%5D=ati_month_en%3AJuly&ati%5B1%5D=ati_month_en%3AMarch&ati%5B2%5D=ati_organization_en%3APatented%20Medicine%20Prices%20Review%20Board%20Canada
    (Report an issue with citation)
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 26 record(s)

Nothing to report this month

Organization: Patented Medicine Prices Review Board Canada

March 2024

Req # A-2022-05111

Electronic copies of the following documents. In all cases, cabinet confidences may be excluded and draft versions of documents. In all of the requests below, “draft guidelines” refers to the PMPRB Guidelines that were published for comment on October 6, 2022, or any prior drafts or versions of those 2022 Guidelines (for example, if a draft version was circulated to Health Canada for comment in September 2022, it would be part of the “draft guidelines” for the purpose of this request). • Emails or other communications from Health Canada commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Emails or other communications from the Board members or Board Chair commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Any training presentations, training manuals, or summaries of the new guidelines prepared for use by the Board Staff, Board, or other governmental departments prepared between July 1, 2022, and October 6, 2022. • Any documents with calculations of how much prices will decrease under the draft guidelines, or under alternative pricing rules, and that were prepared between January 1, 2022, and October 6, 2022 (note the change in date relative to other requests). • Any documents comparing prices or price reductions under the draft guidelines and the old PMPRB Compendium of Guidelines and Procedures. • Any documents, including legal memos, on the compliance of the draft guidelines with legal decisions about the PMPRB, including Alexion Pharmaceuticals Inc. v. Canada (Attorney General), 2021 FCA 157, Merck Canada c Canada, 2022 QCCA 240, and Innovative Medicines Canada v. Canada (Attorney General), 2020 FC 725. • Any documents which discuss how a medicine’s therapeutic class and comparator products will be established under the draft guidelines. • Any documents showing how the Board Staff arrived at the exact pricing tests discussed in paragraph 33-35 of the draft Guidelines. • Any documents which discuss how Board Staff will assess whether a price is excessive *after* an investigation has been opened. For context, the backgrounder which accompanied the draft guidelines suggested that staff will consider “the totality of the circumstances surrounding the price of the medicine, through the lens of the section 85 factors.

Organization: Patented Medicine Prices Review Board Canada

197 page(s)
July 2023

Req # A-2023-025211

With regard to the c. 2003 HDAP Report on New Patented Drug - Angiomax (http://www.pmprbcepmb.gc.ca/view.asp?ccid=583), I am looking for a copy of any supporting research, reports and calculations used to determine dosage regimens. I am specifically interested in how these quantities (in mL) were derived, the benchmark patient weight that was used (in kg) and the timeframe of the dosing.

Organization: Patented Medicine Prices Review Board Canada

18 page(s)
July 2023

Req # A-2023-025599

For FY 2015-2022 (inclusive), how many investigations into prescription pricing on the basis that the pricing exceeded the guidelines resulted in a public hearing? Of those that resulted in a public hearing, in how many was the pricing found to be excessive? Of those that were found to be excessive, how many resulted in orders to reduce the prescription price?

Organization: Patented Medicine Prices Review Board Canada

1 page(s)
July 2023

Req # A-2023-025896

For fiscal years 2015-2022 (inclusive), how many new patented medicines were reported to the board by Bayer, Inc.? From among those reports, how many included claims that a price exceeded the guidelines?

Organization: Patented Medicine Prices Review Board Canada

588 page(s)
July 2023

Req # A-2023-025600

For FY 2015-2022 (inclusive), how many Advance Certificate Rulings were issued by the board?

Organization: Patented Medicine Prices Review Board Canada

0 page(s)
July 2023

Req # A-2023-09059

Copies of all submissions or comments received in response to the PMPRB's 2022 Guidelines consultation, including any late consultation submissions received on December 6th or 7th, 2022. This request runs from October 6th to December 7th, 2022. If Health Canada or any other federal government department provided comments outside of the consultation process I would like a copy of those comments as well. This part of the request also runs from October 6th to December 7th, 2022.

Organization: Patented Medicine Prices Review Board Canada

81 page(s)
March 2023

Req # A-2023-03268

Part 1: Based on documents disclosed in A-2022-09063, (see PDF pages 67-68), the PMPRB sent a letter to the Minister of Health on or around November 30, 2022. I would like to request a copy of that letter, as well as any response from Health Canada. Part 2: Based on documents disclosed in A-2022-09063, a meeting of the PMPRB occurred on December 5th, 2022 (see PDF page 19 of A-2022-09063). I would like to request the following records related to that meeting: 1. A list of attendees for the meeting. 2. A copy of the calendar invitation for the meeting (regardless of program: Outlook, Google meetup, etc), including any attachments to the invite. 3. The agenda for the meeting. 4. The minutes of the meeting. 5. Any notes taken by participants in the meeting. 6. Any documents distributed or discussed during the meeting (such as handouts or powerpoints). 7. Any emails sent by the participants in the meeting which summarized the meeting or discussed next steps.

Organization: Patented Medicine Prices Review Board Canada

4 page(s)
March 2023

Req # A-2023-03897

We read the article entitled "After pharma lobbying, minister intervened to suspend drug-price reform" published by the media "The Breach": https://breachmedia.ca/after-pharma-lobbying-minister-intervened-tosuspend-drug-price-reform/ We understand that someone from "The Breach" (its author Kelly Crowe or someone else) has requested information from the PMPRB to write the article. We cannot find this request through the archives of the Access to Information and Personal Information Online Request Service. We therefore request all communication, records and documents which were communicated in this request and/or relating to the information behind the aforementioned article which have been provided to The Breach or its employees.

Organization: Patented Medicine Prices Review Board Canada

0 page(s)
March 2023

Req # A-2022-13654

Electronic copies of the following documents: 1. A copy of every advance ruling certificate (ARC) issued by the Board, including any reasons in support of the ARC issued by the Board. 2. A copy of the Notice and Comment issued by the Board in response to each of the ARCs. 3. A copy of the patentee's submissions (including any affidavits or other evidence) on each of the ARCs. The Board's ARC for Viread indicates that these submissions are available upon request. 4. A copy of the Board Staff's submissions (including any affidavits or other evidence) on each of the ARCs. Again, the Board's Viread ARC indicates that these are available upon request. 5. A copy of any other submissions received in response to the notice of and comment.

Organization: Patented Medicine Prices Review Board Canada

97 page(s)
July 2022
Date modified: